CHRD

Across TCGA pan-cancer cohorts, CHRD mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CHRD’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where CHRD mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CHRD is over-expressed in tumor, although a few such as LSCC and CCRCC show the opposite, repressed pattern.

LSCC, CCRCC, and PDAC are the cancer types where CHRD tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHRD mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	II,III,IV	−0.623	<.001	8	view →
CCRCC	Male	III,IV	−0.532	.022	2	view →
PDAC	All	IV	+0.543	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

CHRD–LSCC

Open the LSCC breakdown →